000276076 001__ 276076
000276076 005__ 20240918111558.0
000276076 0247_ $$2doi$$a10.1038/s41523-023-00546-x
000276076 0247_ $$2pmid$$apmid:37173335
000276076 0247_ $$2pmc$$apmc:PMC10182045
000276076 0247_ $$2altmetric$$aaltmetric:148275227
000276076 037__ $$aDKFZ-2023-00982
000276076 041__ $$aEnglish
000276076 082__ $$a610
000276076 1001_ $$00000-0002-5895-1808$$aMuranen, Taru A$$b0
000276076 245__ $$aPREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.
000276076 260__ $$aLondon$$bNature Publ. Group$$c2023
000276076 3367_ $$2DRIVER$$aarticle
000276076 3367_ $$2DataCite$$aOutput Types/Journal article
000276076 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726650934_14745
000276076 3367_ $$2BibTeX$$aARTICLE
000276076 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276076 3367_ $$00$$2EndNote$$aJournal Article
000276076 520__ $$aWe assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC). PREDICT for estrogen receptor (ER)-negative breast cancer had modest discrimination for BRCA1 carrier patients overall (Gönen & Heller unbiased concordance 0.65 in CIMBA, 0.64 in BCAC), but it distinguished clearly the high-mortality group from lower risk categories. In an analysis of low to high risk categories by PREDICT score percentiles, the observed mortality was consistently lower than the expected mortality, but the confidence intervals always included the calibration slope. Altogether, our results encourage the use of the PREDICT ER-negative model in management of breast cancer patients with germline BRCA1 variants. For the PREDICT ER-positive model, the discrimination was slightly lower in BRCA2 variant carriers (concordance 0.60 in CIMBA, 0.65 in BCAC). Especially, inclusion of the tumor grade distorted the prognostic estimates. The breast cancer mortality of BRCA2 carriers was underestimated at the low end of the PREDICT score distribution, whereas at the high end, the mortality was overestimated. These data suggest that BRCA2 status should also be taken into consideration with tumor characteristics, when estimating the prognosis of ER-positive breast cancer patients.
000276076 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000276076 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276076 7001_ $$aMorra, Anna$$b1
000276076 7001_ $$00000-0003-4185-8882$$aKhan, Sofia$$b2
000276076 7001_ $$aBarnes, Daniel R$$b3
000276076 7001_ $$aBolla, Manjeet K$$b4
000276076 7001_ $$00000-0003-4591-1214$$aDennis, Joe$$b5
000276076 7001_ $$00000-0002-5452-9933$$aKeeman, Renske$$b6
000276076 7001_ $$00000-0001-5756-6222$$aLeslie, Goska$$b7
000276076 7001_ $$00000-0003-3242-8477$$aParsons, Michael T$$b8
000276076 7001_ $$aWang, Qin$$b9
000276076 7001_ $$00000-0003-0771-7752$$aAhearn, Thomas U$$b10
000276076 7001_ $$aAittomäki, Kristiina$$b11
000276076 7001_ $$00000-0002-4226-6435$$aAndrulis, Irene L$$b12
000276076 7001_ $$aArun, Banu K$$b13
000276076 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b14$$udkfz
000276076 7001_ $$aBialkowska, Katarzyna$$b15
000276076 7001_ $$aBojesen, Stig E$$b16
000276076 7001_ $$aCamp, Nicola J$$b17
000276076 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b18$$udkfz
000276076 7001_ $$aCzene, Kamila$$b19
000276076 7001_ $$00000-0002-8023-2009$$aDevilee, Peter$$b20
000276076 7001_ $$ainvestigators, HEBON$$b21$$eCollaboration Author
000276076 7001_ $$aDomchek, Susan M$$b22
000276076 7001_ $$aDunning, Alison M$$b23
000276076 7001_ $$aEngel, Christoph$$b24
000276076 7001_ $$00000-0002-8482-5784$$aEvans, D Gareth$$b25
000276076 7001_ $$aGago-Dominguez, Manuela$$b26
000276076 7001_ $$00000-0003-1033-2650$$aGarcía-Closas, Montserrat$$b27
000276076 7001_ $$aGerdes, Anne-Marie$$b28
000276076 7001_ $$aGlendon, Gord$$b29
000276076 7001_ $$aGuénel, Pascal$$b30
000276076 7001_ $$aHahnen, Eric$$b31
000276076 7001_ $$0P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b$$aHamann, Ute$$b32$$udkfz
000276076 7001_ $$aHanson, Helen$$b33
000276076 7001_ $$aHooning, Maartje J$$b34
000276076 7001_ $$aHoppe, Reiner$$b35
000276076 7001_ $$00000-0003-1258-4843$$aIzatt, Louise$$b36
000276076 7001_ $$00000-0002-5650-0501$$aJakubowska, Anna$$b37
000276076 7001_ $$00000-0002-4361-4657$$aJames, Paul A$$b38
000276076 7001_ $$aKristensen, Vessela N$$b39
000276076 7001_ $$aLalloo, Fiona$$b40
000276076 7001_ $$00000-0001-9386-2416$$aLindeman, Geoffrey J$$b41
000276076 7001_ $$aMannermaa, Arto$$b42
000276076 7001_ $$aMargolin, Sara$$b43
000276076 7001_ $$00000-0001-5053-0390$$aNeuhausen, Susan L$$b44
000276076 7001_ $$00000-0002-6382-4678$$aNewman, William G$$b45
000276076 7001_ $$00000-0001-6951-6855$$aPeterlongo, Paolo$$b46
000276076 7001_ $$aPhillips, Kelly-Anne$$b47
000276076 7001_ $$aPujana, Miquel Angel$$b48
000276076 7001_ $$aRantala, Johanna$$b49
000276076 7001_ $$aRønlund, Karina$$b50
000276076 7001_ $$00000-0002-0485-0120$$aSaloustros, Emmanouil$$b51
000276076 7001_ $$aSchmutzler, Rita K$$b52
000276076 7001_ $$aSchneeweiss, Andreas$$b53
000276076 7001_ $$aSinger, Christian F$$b54
000276076 7001_ $$00000-0001-9271-7778$$aSuvanto, Maija$$b55
000276076 7001_ $$00000-0003-1063-5352$$aTan, Yen Yen$$b56
000276076 7001_ $$00000-0002-4896-5982$$aTeixeira, Manuel R$$b57
000276076 7001_ $$aThomassen, Mads$$b58
000276076 7001_ $$aTischkowitz, Marc$$b59
000276076 7001_ $$aTripathi, Vishakha$$b60
000276076 7001_ $$aWappenschmidt, Barbara$$b61
000276076 7001_ $$aZhao, Emily$$b62
000276076 7001_ $$00000-0003-2444-3247$$aEaston, Douglas F$$b63
000276076 7001_ $$aAntoniou, Antonis C$$b64
000276076 7001_ $$aChenevix-Trench, Georgia$$b65
000276076 7001_ $$00000-0001-8494-732X$$aPharoah, Paul D P$$b66
000276076 7001_ $$00000-0002-2228-429X$$aSchmidt, Marjanka K$$b67
000276076 7001_ $$aBlomqvist, Carl$$b68
000276076 7001_ $$00000-0002-0916-2976$$aNevanlinna, Heli$$b69
000276076 773__ $$0PERI:(DE-600)2843288-5$$a10.1038/s41523-023-00546-x$$gVol. 9, no. 1, p. 37$$n1$$p37$$tnpj Breast cancer$$v9$$x2374-4677$$y2023
000276076 909CO $$ooai:inrepo02.dkfz.de:276076$$pVDB
000276076 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000276076 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000276076 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b$$aDeutsches Krebsforschungszentrum$$b32$$kDKFZ
000276076 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000276076 9141_ $$y2023
000276076 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-10-13T14:24:54Z
000276076 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-22
000276076 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-22
000276076 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-22
000276076 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-22
000276076 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ BREAST CANCER : 2022$$d2023-10-27
000276076 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000276076 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000276076 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000276076 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:12:14Z
000276076 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:12:14Z
000276076 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:12:14Z
000276076 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000276076 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000276076 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-27
000276076 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ BREAST CANCER : 2022$$d2023-10-27
000276076 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000276076 9201_ $$0I:(DE-He78)B072-20160331$$kB072$$lMolekulargenetik des Mammakarzinoms$$x1
000276076 9201_ $$0I:(DE-He78)B070-20160331$$kB070$$lB070 Funktionelle Genomanalyse$$x2
000276076 980__ $$ajournal
000276076 980__ $$aVDB
000276076 980__ $$aI:(DE-He78)C020-20160331
000276076 980__ $$aI:(DE-He78)B072-20160331
000276076 980__ $$aI:(DE-He78)B070-20160331
000276076 980__ $$aUNRESTRICTED